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Goiás, Goiás, Brazil; 17Federal University of Pernambuco, Recife, BrazilA B S T R A C TObjectives: The overall aim of this article was to present a step-by-step
guideline for determining the costs associated with dengue in dengue-
endemic countries of the Latin American and the Caribbean region and
to illustrate how each of these steps can be applied in dengue costing
studies. Methods: An expert panel was convened to develop standards
for costing dengue so that over the next decade, decision makers will
have access to improved information on the true cost of dengue in
endemic countries of the Latin American and the Caribbean region. We
described the outcome of the expert panel meeting, which resulted in
the provision of a step-by-step dengue costing guideline that aims to
provide direction to planners and program managers on how to
estimate dengue economic burden studies, and provide a discussion
forum of the methods used to cost dengue fever cases and outbreaks in
a manner that should be accessible to persons with some familiarityee front matter Copyright & 2015, International S
r Inc.
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st: The authors have indicated that they have no
@jhu.edu.
ndence to: Dagna Constenla, 855 North Wolfe Strewith a cost study. Results: The guideline includes nine sequential steps:
1) deﬁnition of the scope of the study; 2) identiﬁcation of the target
population; 3) description of the study perspective; 4) deﬁnition of the
time horizon; 5) calculation of the sample size; 6) deﬁnition of the unit
of analysis; 7) identiﬁcation of the cost items; 8) measurement and
valuation of the cost items; and 9) handling of uncertainty. The trade-off
between accurate, patient-level cost estimates and data availability
constraints is discussed. Conclusions: The current guideline is the
result of constructive collaboration among a multidisciplinary research
team to better ascertain the true economic burden of dengue across
countries of the region.
Keywords: costing, dengue fever cases, dengue outbreaks.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Background
Dengue is the vector-borne viral infection most widely and
further spread in the world, representing a severe public health
problem. Dengue is caused by one of four serotypes (Denv1,
Denv2, Denv3, and Denv4), transmitted by several species of
mosquito within the genus Aedes aegypti. This disease has no
boundaries or limits, affecting populations of all ages and socio-
economic levels. It is estimated that 390 million dengue infec-
tions are reported every year, with 70% of the 96 million clinical
dengue infections reported occurring in Asia, followed by 16% in
Africa and 14% in the region of Latin America and the Caribbean[1]. The dramatic increase in dengue cases is due to a number of
factors, including population growth, urbanization, and increased
international travel. Dengue has a high social and economic
impact, affecting not just the patient but also the family and
the community in which those affected by dengue live. The true
economic cost of the disease is unknown; however, it is believed
to range from US $13.5 million (Nicaragua) to US $56 million
(Malaysia) [2].
Limited research has been done to estimate the costs of
dengue in the Latin American and Caribbean region. In a recent
review of the literature, only a handful of economic studies were
found in the region [2]. The studies reviewed indicated anociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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in case classiﬁcation, deﬁnition of cost categories, sampling, data
sources, and other methodological challenges. In addition, the
published literature shows that studies looking at dengue cost
estimates are not of sufﬁcient quantity and quality. It is not
always clear from these economic studies which form of treat-
ment associated with dengue is costed, what is included in the
total cost estimation of dengue, and how these estimates are
calculated. Moreover, cost estimates from these studies are of
heterogeneous (mixed) quality, not generalizable to other pop-
ulations, and not representative of the total economic conse-
quences of dengue.
These methodological issues are compounded by the absence
of well-established guidelines for costing diseases such as
dengue. Efforts by governments and health care systems in the
United States, Europe, Asia, Latin America, and the Caribbean to
harmonize approaches to economic evaluation are ongoing, but
the task is challenging. With governments and health care
systems continuing to take an independent line on evaluation,
the scientiﬁc community is left in a difﬁcult position, given the
international basis of its research activities [3]. The impetus of
conducting dengue cost studies is that they can be used as
inputs into cost-effectiveness analyses to provide important
information about efﬁcient resource allocation and health care
ﬁnancing [4–6].
Cost studies can be performed across various delivery set-
tings, such as hospitals or primary care centers; in different
geographic areas, from urban to rural hospitals and primary care
centers; and in different socioeconomic settings, from high-
income households to low-income households [2]. Because of
the limited research that has been done to estimate dengue costs
across various health care delivery settings, geographic areas,
and socioeconomic settings, and to estimate the consequences of
dengue in settings outside the health care system (e.g., tourism),
there is little development of the necessary underlying theory of
economic costs of dengue and limited data systematically col-
lected for this purpose are available.
Many guidelines have been developed to direct the design and
conduct of economic studies, comprising an analysis of the costs
and effects of an intervention. Most of the guidelines are from
developed countries [6–9], where data are more readily available,
and are not disease-speciﬁc. From preliminary discussions with
experts in the region, we found a few country-speciﬁc economic
evaluation guidelines in dengue-endemic countries of the region
[10–12]. The overriding constraint when costs are estimated in
these settings is the lack of ﬁnancial records and incomplete
patient disease registers, as well as the limited expertise in
conducting costing studies. These issues are compounded by
the fact that there is little consensus on which guidelines to
adopt to estimate the true costs of disease.
In response to the growing need for dengue cost estimates to
inform future vaccine introduction, an expert panel was con-
vened on March 6–8, 2012 to discuss and develop a standardized
methodology for estimating costs of dengue in the Americas [13].Aim and Objectives
The overall aim of this article was to present a step-by-step
guideline for determining the costs associated with dengue in
dengue-endemic countries of the region and to illustrate how
each of these steps can be applied in dengue costing studies. The
guideline is regional in scope and includes nine sequential steps:
1) deﬁnition of the scope of the study; 2) identiﬁcation of the
target population; 3) description of the study perspective; 4)
deﬁnition of the time horizon; 5) calculation of the sample size;
6) deﬁnition of the unit of analysis; 7) identiﬁcation of the costitems; 8) measurement and valuation of the cost items; and 9)
handling uncertainty. Because a cost study has many different
methodological components built from extensive theoretical and
operational evidence of their comprising disciplines, it is not
possible to cover all the diverse dengue-related costing issues.
Only areas of priority to the expert panel are highlighted in this
article [13].Methods
On the basis of a systematic review of the literature and an expert
survey described elsewhere [2], we developed a framework to cost
dengue cases and outbreaks in the Americas. Two key elements
were central to the development of this framework: 1) the type of
standard methods needed to capture the true economic cost of
dengue, and 2) the type of cost information that is most useful to
making public health policies to counter dengue infections. We
convened a panel of experts to identify methodological gaps in
this area and discuss recommendations to measure the true cost
of dengue. The overall approach used to develop the guideline is
discussed elsewhere [13].
In brief, the guideline was developed using a stepwise
approach starting with a provisional guideline developed by a
multidisciplinary group of experts who attended a workshop in
2012. The guideline was based on existing evidence and exten-
sive small and large group discussions and formal didactic
sessions. A working group was then formed to review recom-
mendations from the guideline, address common methodolog-
ical issues when costing dengue, and assess the scientiﬁc
validity of the guideline. Much like the original expert panel
convened for the workshop, the working group was composed of
health economists from various countries in the Americas,
including epidemiologists, entomologists, program managers,
and policymakers with background or expertise in dengue or
dengue economics.Deﬁning Dengue
The lack of accuracy around dengue cost estimates is in large
part due to the uncertainty of what to measure. There is
considerable uncertainty surrounding the case and outbreak
deﬁnitions, and what deﬁnitions are known vary across coun-
tries and regions. Experts agreed about the need to be explicit
and consistent about the use of the dengue case deﬁnition and
to distinguish where these cases are being reported (e.g.,
ambulatory vs. hospitalized dengue cases) because the costs
differ across settings, and to characterize how these cases are
being reported (e.g., suspected dengue cases, probable dengue
cases, and conﬁrmed dengue cases). In this section, we discuss
dengue case and outbreak deﬁnitions based on in-depth expert
discussions and address some of the key challenges of deﬁning
dengue.
Dengue Cases
Measurement of the local burden of disease is an essential
component of dengue cost evaluations. When data on disease
burden are lacking, policymakers may perceive that the disease
is not important and the beneﬁts of prevention and control
strategies (e.g., vector control and vaccines) will not be appre-
ciated. To estimate the burden of dengue, key outcomes of
infection need to be identiﬁed. Difﬁculties arise because of
inconsistencies in case deﬁnitions for dengue, overlapping clin-
ical features with other illnesses, nonspeciﬁc and/or expensive
diagnostic tools, and reliance on verbal autopsy to estimate
mortality ﬁgures.
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estimates of dengue burden in the region, more comprehensive
information on the amount of dengue is likely to be provided by
phase III efﬁcacy trials. It is possible that, as is the case with
many clinical trials, results of previous studies will prove to be
signiﬁcant underestimates of the true burden of dengue. Fur-
thermore, disease burden may be underestimated in the vaccine
trial because of the high speciﬁcity of case deﬁnitions.
Ideally, data on disease burden should be available from all
countries to ensure that decision makers appreciate the true
economic consequences of dengue and the potential beneﬁts of
control and prevention strategies in their setting. In reality,
however, given the difﬁculties that exist in establishing disease
surveillance, this is unlikely to ever be the case. It is therefore
important that surveillance be instituted on a regional basis and
that case deﬁnitions used in clinical trials be standardized to
facilitate transfer of results.
Over recent decades, there has been extensive debate regard-
ing dengue case deﬁnitions. The World Health Organization
(WHO) case classiﬁcation of dengue fever, dengue hemorrhagic
fever, and dengue shock syndrome was originally formulated in
1974 by a technical advisory committee on the basis of studies of
disease patterns in patients in Thailand in the 1960s [14]. Some
modiﬁcations to this deﬁnition were made in 1997 [14], and in
2006, the WHO Dengue Scientiﬁc Working Group recommended
additional research into dengue diagnostics and triaging of
patients for optimized clinical management [15].
A revised guideline was proposed in 2009 following the 2006
modiﬁcations to account for the geographic expansion of dengue
and its increased incidence in older age groups [16,17], and
current practices in case treatment, hospital laboratory, and
dengue diagnostic methods [14]. The revised 2009 WHO dengue
case deﬁnitions classiﬁed the illness into dengue with and with-
out warning signs and severe dengue. Although the 2009 revi-
sions were more sensitive to the diagnosis of severe dengue, and
beneﬁcial to triage and case management, this classiﬁcation
system was not universally applicable for appropriate clinical
management [18–25].
The 11th revision of the International Classiﬁcation of Diseases
[25] is considering the inclusion of this new classiﬁcation. During
this transition phase, some countries of the region plan to use
the previous classiﬁcation (revised 2009 WHO case deﬁnition);
others will adopt the new classiﬁcation (2011 WHO case deﬁ-
nition) or a modiﬁed version of this deﬁnition. It is unclear,
however, how these countries will adapt these case deﬁnitions
into their ongoing surveillance programs. The Pan-American
Health Organization (PAHO), through the Dengue Regional Pro-
gram, supports member states in the implementation of the
Integrated Management Strategy for the Prevention and Control
of Dengue [26] in which case deﬁnition is part of the integrated
strategy for the surveillance of and preparedness for dengue
cases and outbreaks.
Given that the dengue classiﬁcation is changing, the expert
panel recommends that the approach for costing dengue cases
should be explicit to discriminate at least two types of dengue
cases: cases that are treated in ambulatory settings and cases
that are treated in hospital settings. In addition, dengue cases
should be further stratiﬁed into suspected (clinically diagnosed)
cases, probable cases, and laboratory-conﬁrmed cases. Consid-
erations need to be made, however, when stratifying dengue into
suspected, probable, and laboratory-conﬁrmed cases: 1) not all
countries have adopted the WHO/PAHO case deﬁnition or agree
with the new case deﬁnition, and 2) not all countries have the
capacity to provide laboratory conﬁrmation; therefore, a standard
for case deﬁnition should not be based solely on laboratory
conﬁrmation but on clinical observation as well. All experts
agreed that the old deﬁnition of dengue hemorrhagic fevershould not be used and that conﬁrmed and unconﬁrmed cases
should be costed separately.
Dengue Outbreaks
The International Research Consortium on Dengue Risk Assess-
ment, Management and Surveillance [27] has been seeking con-
sensus on the technical deﬁnition of an outbreak with the intent
to use the deﬁnition for discovery, epidemiologic, or diagnostic
purposes in the absence of conﬁrmatory laboratory tests. In the
absence of a clear deﬁnition, the expert panel deﬁned a dengue
outbreak as the number of cases representing two standard
deviations (SDs) away from the mean of cases. The WHO uses a
similar deﬁnition when describing the process of triggering an
outbreak alert where it tracks the occurrence of current (probable)
cases and compares them with the average number of cases by
week (or month) of the preceding 5 to 7 years, with conﬁdence
intervals set at two SDs above and below the average (2 SD) [24].
This is sometimes referred to as the “endemic channel,” in which
an outbreak alert is triggered if the number of cases reported
exceeds two SDs above the endemic channel in weekly or
monthly reporting. This, however, is not an ofﬁcial dengue
outbreak deﬁnition.
The expert panel agreed that a dengue outbreak can also
mean the conﬁrmation of one or more locally acquired dengue
cases. In this case, one case in an area where no other case has
been reported could be considered an outbreak. Many countries
in the region have used this deﬁnition, but the number of
locally acquired conﬁrmed dengue cases differs by country
and currently there is no standard deﬁnition of a dengue
outbreak. Dengue outbreaks range from a few cases in an urban
area through to large-scale outbreaks with hundreds of cases
across the region. The approach for costing dengue outbreaks
should be similar to the one applied for costing dengue cases—
that the process of deﬁning a dengue outbreak should be
explicit. There are, however, important differences between
suspected cases of dengue occurring during an outbreak and
probable dengue cases and conﬁrmed dengue cases occurring
during an outbreak.Systematic Approach to Estimate the Socioeconomic
Costs of Dengue
The impetus for cost studies is to inform the community about
the economic consequences of dengue. Although the number of
published economic studies has increased substantially over the
past two decades, the quality of these studies has been ques-
tioned [2], and their inﬂuence on program implementation
remains uncertain. Furthermore, many endemic countries do
not have the resources or ﬁnances needed to perform detailed
cost studies. Thus, it is important to promote the use of
generalized approaches to conducting these studies.
Guidelines for estimating costs can be used to plan various
aspects of a cost study including the selection of the sample
frame for data collection and the target population; the collection
of resource utilization and unit cost data; the estimation of the
national economic burden of a disease; and the incorporation of
these data into a cost-effectiveness analysis of preventive inter-
ventions, in particular dengue vaccination and vector-control
strategies. Developing guidelines for the purpose of estimating
costs of dengue is an empiric process. Although it is helpful to
consider certain core principles in deriving guidelines, the appli-
cation of these principles is a complex process that requires
innovative approaches to tackling the myriad of potential factors
involved. Central to the development of costing guidelines is a
clear understanding of the terminology used in costing, cost
V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 8 0 – 9 1 83categories, and study designs used to document the cost impact
of diseases and disease interventions. The following is a dis-
cussion of this process.
Costs and Cost Categories
The terminology used in costing can often be confusing. In much
of the existing literature, the terms “direct,” “indirect,” and
“intangible” have been used to classify the costs (and beneﬁts)
associated with an intervention. The term “direct” generally
refers to changes in resource use (and health) attributable to
the intervention. The term “indirect” is commonly used to denote
time and productivity lost or gained because of the intervention.
Other deﬁnitions of costs have been used, including direct
medical costs (savings), referring to those resources used
(averted) because of the intervention, such as treatment costs
averted; direct nonmedical costs (or non–health care) refer to
costs that are associated directly with provision of medical
services but are non-medical, including travel, and childcare
costs. In view of inconsistencies in deﬁnitions used across studies
and differing interpretation across professional ﬁelds, the expert
panel recommended the use of the following terminology: costs
of disease (health care, non–health care costs), costs associated
with an intervention, and costs associated with foregone
productivity.
Costs of disease include the costs directly related to treatment
(e.g., physician services, ambulatory and hospital care, antibiotic
therapy, laboratory and diagnostic studies, surgical procedures,
nursing, and supplies). These costs are also referred to as direct
health care costs or direct medical costs. Also included in this
category are care costs for parents of sick children attending the
hospital or clinic, transport costs to and from the hospital or
clinic, costs of over-the-counter medications, and home care
costs. These are referred to as direct non–health care costs or
direct nonmedical costs.
Costs associated with an intervention include the interven-
tion costs, costs to participants of the intervention, and costs
associated with side effects (or adverse events) of the interven-
tion. The costs of the intervention comprise the price of the
intervention, supplies and equipment, facilities, and storage. The
costs to participants include all out-of-pocket expenses and
productivity losses resulting directly from the intervention.
Finally, the costs associated with side effects are related to the
intervention itself.
Costs associated with foregone productivity resulting from an
intervention and its consequences can be considered, as well as
the cost of personal care to patients and their families, travel or
informal care, and ﬁxed intervention costs resulting from the
intervention and its consequences. Loss of productivity that can
arise from reduced productivity of working parents of individuals
who have dengue should also be considered as are costs asso-
ciated with lost or impaired ability to work or enjoy other
activities or days absent from preschool due to disease. Com-
monly, this important component is omitted in the calculation of
disease costs because it is more difﬁcult to calculate than
production losses. There are often problems associated with the
estimation of indirect costs. These difﬁculties are partly attribut-
able to the fact that indirect costs are borne by the individuals
and their families whereas direct (medical) costs are generally
incurred by public agencies and hence are more readily valued
and measurable. Despite difﬁculties in estimating indirect costs
in cost studies, it is a worthwhile process at the very least to
establish the order of magnitude of such costs.
A related issue, probably of importance in some countries, is
the inclusion of beneﬁt payments for disability or sickness. These
are generally considered to be “transfer payments” and not
economic costs from a broad societal perspective. They may,however, be important from a government regulatory perspective.
The importance of obtaining information on different cost cate-
gories and/or beneﬁt payments in individual countries, by means
of a further side study of a subsample of infants and young
children, should be considered when costing dengue as part of a
country requirement.
The order of magnitude of the costs (disease-related, inter-
vention-related, and costs of productivity foregone) varies widely.
Some differences may be accounted for by the fact that cost
studies are conducted in different settings and different cost
components are considered for diseases such as dengue. Cost
differences can also be attributable to their exclusion of some or
all disease and/or intervention costs and possible exclusion of
important costs associated with foregone productivity. This
raises the issue of what costs to include in cost studies. Although
in theory all relevant costs should be included, in practice there is
a limit to what can be identiﬁed and measured. The choice of
which type of costs to include in the evaluations is country-
speciﬁc; therefore, categories of costs speciﬁc to each country
need to be developed. In addition, guidelines should be developed
to value these cost categories differently.Financial Costs and Economic Costs
In cost studies, costs should be considered at their opportunity
value. Cost in economic terms is deﬁned as the value of resources
that have been foregone for alternative uses. Economic costs
include the true costs of a disease. The use of economic
(opportunity) cost is optimal because this is the most accurate
way of valuing resource use. There are, however, major chal-
lenges in estimating the opportunity costs. In contrast, ﬁnancial
costs (charges or shadow prices [prices that have been adjusted
to yield economic costs]) are generally considered in the absence
of opportunity costs.
There are important differences between ﬁnancial costs and
economic costs. Financial costs represent the actual expendi-
ture on goods and services purchased and are therefore
described in terms of how much money has been paid for the
resources used, whereas economic (opportunity) costs are
values of the lost beneﬁt because the resource is not available
for its next best use. Using cost data that are ﬁnancial in nature
may be practical though care must be taken to be clear when
ﬁnancial data are used. The expert panel recommends the use
of ﬁnancial cost data from a practical standpoint (when oppor-
tunity costs are not available). They also recommend the use of
the economic (opportunity) costs when data availability and
time allow.Marginal and Average Costs
There are important differences between marginal (incremental)
costs and average costs. The marginal (incremental) cost is the
change in the total costs that arises when the quantity produced
changes by one unit; that is, the additional cost of producing one
more unit of good. Many difﬁculties can stem from the estima-
tion of marginal costs because costs of intervention programs
and annual increases of resources are often unknown.
The average cost considers both the ﬁxed and variable costs
without any consideration to changes in costs. Average costs
typically include the total costs of an intervention, regardless of
pre-existing structures or levels of provision, divided by the
number of persons affected by the intervention. Such costs are
generally higher than marginal costs because they do not account
for preexisting structures or levels of provision common to
intervention programs. The expert panel recommends the use
of the incremental costing and the use of the average cost per
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obtaining ﬁxed costs can be difﬁcult.
Economic Study Methods
A number of techniques focus on disease, intervention, and
productivity foregone cost estimations. These include cost con-
sequence analysis, cost minimization analysis, and cost-of-
illness (COI) study. These techniques differ in the extent to which
they measure and value disease, intervention, and productivity
foregone costs. The cost consequence analysis is a form of
economic evaluation that presents the costs and consequences
of interventions in a natural unit of effect but are reported
separately (costs and consequences are not combined). Another
form of economic evaluation is a cost minimization analysis, and
the aim of this evaluation is to ﬁnd the least costly program
among those shown or assumed to be of equal beneﬁt. The COI
study identiﬁes and evaluates the direct and sometimes indirect
and intangible costs of a particular disease or risk factor. The
expert panel discussed the methodology of the COI study specif-
ically because of its relevance to the guidelines.
COI studies estimate the total costs attributable to a particular
disease rather than a particular intervention. The aim of COI
studies is to establish the true level of the economic burden
imposed by a particular disease so that informed choices can be
made regarding health care resource allocation. This form of
study identiﬁes those elements of cost that might be reduced by
more effective new treatment. In diseases such as dengue, in
which treatment prevents or controls the number of infections
transmitted, the effect of new treatment may be to reduce
disease episodes or disease severity.
One of the beneﬁts of COI studies is identifying the illnesses
that consume the most health care resources and broader societal
perspectives. This form of study introduces an estimate of the
scale of medical problems in terms of the amount of spending. COI
studies, however, have often been criticized for not addressing the
value for money question. In addition, these studies do not
provide any indication of how to improve the economic value of
disease intervention; they do not compare alternative uses of
resources. Instead, they consider the costs of resources consumed
in an intervention or disease. In particular, a high proportion of
direct costs used are often in areas that would not be affected by
new treatments; that is, COI does not identify the potential to
achieve gains. Nevertheless, it is important to be aware of the
costs attributable to dengue, particularly if potential cost savings
could be realized through new and innovative interventions.
There are two distinct approaches to undertaking a COI study:
the prevalence approach and the incidence approach. These
approaches refer to the manner in which costs are attributed to
a particular disease. The prevalence-based cost would estimate
the costs attributable to all individuals suffering from dengue in a
given year. In contrast, an incidence-based cost study would
estimate the present value of the lifetime costs of all individuals
newly diagnosed with dengue in a given year. The incidence
approach is more precise but has more information needs and is
more costly to perform. This approach is generally used to cost
infectious diseases because of their short duration and ﬂuctua-
tion of incidence. The key difference in these two approaches is
the choice of variables or model parameters and outcomes
measured.
In the following pages we present a step-by-step guide for
estimating dengue. This guide provides considerable information
on the estimation of aggregate costs. Although aggregate costs
are extremely valuable for a number of purposes, as an indicator
of the overall economic burden borne by the community as a
result of dengue, they indicate neither the proportion of such
costs that are potentially avoidable nor the nature of theprograms and policies best suited to achieve this cost avoidance.
The current step-by-step guide does not explicitly consider
economic evaluations because regional experts considered the
need for dengue-speciﬁc costing guidelines a priority. Future
versions of the guideline may address other forms of economic
evidence related to dengue. Table 1 describes the steps of the
dengue costing guideline.Step-by-Step Guide
The expert panel agreed that the step-by-step guide should be
based on existing recommendations and should be disease-
speciﬁc. This is to avoid bias and allow comparisons of other
methodologies when possible. In addition, the guide should be
practical to apply in settings with limited data availability,
incomplete patient disease registers, and limited expertise or
experience in conducting costing studies. The following text
describes the step-by-step recommendations that include nine
sequential steps.
Step 1: Deﬁning the Scope of the Analysis
The ﬁrst step to conducting a cost study is to frame the analysis.
Framing the analysis involves deﬁning the problem and the scope
and adopting a research strategy. Decisions made at this stage will
determine which costs are considered relevant and should there-
fore be included in the analysis. Planning a disease-speciﬁc costing
study requires detailed review of local disease burden, its epidemi-
ology, and knowledge of the decision space. The deﬁnition of the
scope of the study is driven primarily by the decision problem. For
example, if a local stakeholder wants to have an understanding of
the true economic burden of dengue in his or her country, country-
speciﬁc estimates of dengue cases and outbreaks may need to be
estimated for at least 1 year. The perspective(s) chosen in this case
would be the societal perspective to include the health care costs
and the costs outside the formal health care. The measures of
resource use and costs would be in accordance with the perspec-
tive chosen. The public sector, as well as the private, social
insurance, and intersectoral sectors, should be considered in the
analysis to allow for various cost components to be estimated. For
example, in the intersectoral sector, it would be important to
consider the costs associated with prevention and control strat-
egies, tourism costs, and other industries. The scope of the study is
also deﬁned by the availability of information (e.g., patient costs,
household costs, institution costs, and state-level costs) and the
need to bring information together for policy.
Step 2: Identifying the Target Population
The target population should be the population exposed to
dengue disease, which can be deﬁned by geographic area; age
group; and the presence of vectors, transmission, and virus
circulation. Geographic areas can be different if the objective is
to have an estimate of the cost per case, the cost per outbreak, or
the cost associated with a surveillance program. For example, for
the cost per case, the geographic areas will depend on the
national health care system. If no difference in cost per case
exists across geographic areas, an endemic area should then be
chosen to capture an adequate number of dengue cases in a
deﬁned time period.
In terms of age groups, a modiﬁed PAHO age group stratiﬁca-
tion system should be considered. The following stratiﬁcation
was proposed by experts: 0- to 4-year-olds, 5- to 9-year-olds, 10-
to 19-year-olds, 20- to 59-year-olds, and those older than 60
years. A further classiﬁcation of 10- to 14-year-olds and 15- to 19-
year-olds should also be considered to account for the sizeable
burden of disease in these age groups in certain countries (e.g., in
Table 1 – Step-by-step guideline for costing dengue cases and outbreaks.
Steps Recommendations
Step 1: Deﬁne scope of
analysis
Criteria: knowledge of disease burden, availability of data and reproducible tools, surveillance system in
place, assessment of social impacts.
Public sector: entomological surveillance, epidemiological surveillance, prevention and control, management
practice.
Private sector: epidemiological surveillance (active/passive), management practice.
Social insurance sector: epidemiological surveillance (active/passive), management practice, death-related.
Intersectoral sector: prevention and control, tourism, ﬁnance, death-related.
Scope of analysis depends on the study objective but generally includes the cost to the patient, household,
institution, state, and others.
Step 2: Identify target
population
Target population stratiﬁed: 0–4 y, 5–9 y, 10–14 y, 15–19 y, 20–59 y,460 y, reﬂecting on disease burden, based
on PAHO age stratiﬁcation. Geographic areas deﬁned by areas of transmission, high incidence, and historic
trends. Stratify by low-, medium-, and high-transmission to account for geographic variations.
Step 3: Deﬁne study
perspective
Preference: society, which is the broadest perspective because it captures all costs and all health effects,
regardless of who pays for dengue treatment or who is the beneﬁciary of that treatment. This will depend
on the decision problem.
Step 4: Deﬁne time horizon Preference: 1-y duration that includes all seasonal changes within that year. Alternatively, 3-y projections to
evaluate the cost of preventive program and to account for seasonal variations from year to year. Study
should be conducted during a period of substantial transmission in a particular country.
Step 5: Calculate sample
size
Representativeness of data is key. Distinction between the sample size of an observational study and an
economic study is important. Methodology will depend on the number of sites, settings (outpatient,
inpatient), age groups, perspectives (private, public), and 2009 revised WHO dengue case classiﬁcation (e.g.,
DF and DHF). This should be independent of which sector it comes from. A margin of error of 0.5 with low
SDs should be considered. Establish criteria for sampling.
Step 6: Deﬁne the unit of
analysis
Health care resources: hospitalized patients and outpatients.
Program resources: vector control, education, community mobilization, and surveillance.
Productivity-related resources: missed work, education, and community mobilization.
Multisectoral resources: tourism, foreign direct investment, long-term fatigue and depression, outbreak
control, and surveillance spending.
Step 7: Identify cost items A “menu” of cost components for dengue cost evaluations. These include 1) health care activities, 2) program
activities, 3) activities related to productivity, and 4) intersectoral activities.
Step 8: Measure and value
cost items
Accurate description of the process of treatment or the program being used to monitor disease needed. This
involves the measurement of the speciﬁc quantities of resources consumed during the process of
treatment or monitoring: development of a classiﬁcation system; deﬁnition of intervention activities and
cost categories within each activity; measurement of resource use data in physical units; and conversion
of resource data into cost data.
Differentiate between average vs. marginal costs; opportunity costs vs. hospital charges, center-speciﬁc costs
vs. average costs.Adjustments need to be made for inﬂation and currency including discounting, inﬂation,
and purchase power parity. The common currency used is international dollars.
Step 9: Handle uncertainty Need to consider four different types of uncertainty: 1) data sources; 2) generalizability; 3) extrapolation; and
4) analytic method. Inadequate sample sizes, skewed cost data, discount rates, and unit costs may
introduce additional uncertainty. Extensive sensitivity analysis needs to be performed to deal with these
uncertainties.
DF, dengue fever; DHF, dengue hemorrhagic fever; PAHO, Pan-American Health Organization; WHO, World Health Organization.
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important caveat when stratifying the target population is to
determine whether there are any differences in cost per case
found at the country level. If no differences in costs are expected
for ages ranging from 5 to 9 years and 10 to 14 years, for example,
a split in age groups should not be considered. Other consider-
ations include geographic areas deﬁned by areas of transmission
and historic trends in incidence and mortality.
Step 3: Deﬁning the Study Perspective
Decisions regarding the perspective of a costing dengue study
need to be made in the planning phase of the study. Although in
many ways, the scope includes the study perspective, the Costing
Dengue Working Group felt that it was necessary to list this and
step 1 as distinct steps so that appropriate attention could be
drawn to the two steps. The decision problem of a dengue costing
study relates to the resource requirements of providing denguecontrol and prevention care in the hospital and ambulatory
centers. This decision problem determines the study perspective.
The perspective that is taken determines which costs to include,
as well as how to value these costs.
The societal perspective is by far the broadest perspective
because it captures all costs and all health effects, regardless of
who pays for dengue treatment or who is the beneﬁciary of that
treatment. The adoption of a societal perspective would therefore
be advisable because data can be disaggregated and analyzed
from a number of viewpoints. Costs from the societal perspective
include the costs associated with dengue management and
prevention and the household costs before, during, and after a
dengue occurrence, costs associated with surveillance and pro-
gram prevention at municipal, state, and country levels, costs
associated with patient or caregiver absenteeism, and intersec-
toral costs that relate to costs outside the health care sector.
Adopting a societal perspective is challenging; the valuation of
productivity losses is difﬁcult when a large proportion of the
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work. Assigning a value to long-term disabilities and estimating
costs outside the health care sector is also difﬁcult. Data avail-
ability constraints are also important impediments to adopting a
societal perspective in a dengue costing study.
Most decisions about dengue prevention and control may be
taken from the health service perspective or the perspective of
the Ministry of Health. Even though their decisions have a
bearing on society at large, decision makers in these countries
may generally be concerned with direct costs because these are
most indicative of their immediate budgets. In view of the fact
that dengue prevention and control are generally publicly funded
and there is evidence of a small economic family burden of
dengue in these countries, the use of alternative (narrower)
viewpoints, including the health service perspective, is also
recommended. If the objective is to carry out a cost study of a
dengue intervention program from the point of view of the
government health sector, only public health providers (e.g.,
clinics and primary-, secondary-, and tertiary-level hospitals)
and social security providers, in some cases, should be included.
Step 4: Deﬁning the Time Horizon
Choosing an appropriate time horizon for the evaluation of
dengue costs requires consideration of the major short- and
long-term economic outcomes resulting from dengue prevention
and control interventions. It is important to capture not only the
intended costs, but also the costs associated with side effects of
interventions, which may be unintended. The period of analysis
of most of the dengue economic studies published thus far vary
greatly among the literature [2]. Most of the studies involve a
relatively short period of analysis (0–1 year), whereas only a
handful consider a period of analysis of 2 to 5 years, 6 to 10 years,
or more than 10 years. Studies with a short period of analysis do
not capture the long dengue interepidemic intervals or seasonal
ﬂuctuations.
The time frame of the study depends on the speciﬁc objectives
of the study. In some countries, dengue exhibits a seasonal
pattern, with a peak typically occurring in the “rainy” months.
If the purpose is to estimate the overall costs of dengue, the study
should initially cover a full year and should reﬂect the seasonal
variations. If, however, the purpose of the study is to estimate the
costs of dengue or the cost of a speciﬁc outbreak, data collection
should focus on the patients treated during the highest incidence
of dengue. Further projections should be made for additional
periods of time (3–5 years) to take into account the seasonal
ﬂuctuations of dengue that vary from one year to the next and
the long-term fatigue due to dengue. During this period, data can
be reviewed retrospectively (3–5 epidemic years) and modeled to
estimate the average cost of dengue.
As part of the valuation of costs, all future costs in a cost
evaluation should be stated in terms of their present value. To
convert the costs associated with dengue, which may be incurred
at different points in time, to a present value, a process called
discounting is recommended. In discounting, costs (and beneﬁts)
are reduced to their present values by a process of deﬂating
future costs and beneﬁts by an increasing proportion.
There is a bit of controversy surrounding the issue of what
discount rate to use or how to convert future health care beneﬁts
using discounting as the basis. Current guidelines recommend
using a discount rate of both 3% and 5%; however, it is also
recommended that data should be provided undiscounted to
allow recalculation by the reader at any rate. The controversy
surrounding the issue of what discount rate to use or how to
convert future health care costs using discounting as the basis
was discussed during the workshop. A discount rate of both 3%
and 5% for future costing evaluations should be considered. Theundiscounted costs should be presented when the discounted
costs are reported.
Step 5: Calculating the Sample Size
The sample size calculation in a costing study determines the
ability to identify signiﬁcant differences in costs between groups.
When economic studies are conducted alongside clinical trials or
surveillance systems, sample sizes are commonly determined by
the requirements of the trial or surveillance program to demon-
strate the statistical signiﬁcance of the results for the clinical end
points. In this case, sample size requirements for costing studies
are often larger than those for clinical trials or surveillance
systems, due to the need to capture the high variability in cost
data associated with skewed distributions of resource use data.
Various methods for calculating sample sizes were advocated
by the expert panel, including calculating the number of subjects
needed to rule out unacceptably high upper conﬁdence limits for
the cost estimates. Experts agreed that the representativeness of
cost estimates is a key to determining the study sample. The
main question to address is what sample size is needed to ensure
that empirical estimates are close to the true value of the study
population. Overall, the sample size should depend on the size of
the country, the disease burden by some disaggregated informa-
tion, if possible, such as age, severity, region, availability, and
quality of data within the country, and the study question.
The methodology used for the sample size calculation will
depend on the variables that contain the different type of costs
such as the number of sites, settings (outpatient or inpatient), age
groups, perspectives (private or public), and disease classiﬁcation
(e.g., dengue fever and dengue hemorrhagic fever). Some experts
in the panel felt that the inclusion of around 100 patients per
stratiﬁcation should give a robust estimation of the cost per case
with a low SD, as seen in previous studies (e.g., in Vietnam). A
sufﬁcient number of patients per stratiﬁcation should be included
to ensure a statistical calculation of an average cost per case.
Experts did not agree on what the “minimum number” should be.
One of the key issues about the sampling question is the issue
of what is an acceptable point estimate that is of sufﬁcient
evidence for adoption of the intervention under question. The
data used in the evaluation should be considered to provide a
measure of the precision of the cost estimate in light of sampling
uncertainty. Some of the more common measures of sampling
uncertainty include conﬁdence intervals around cost estimates,
conﬁdence intervals for net monetary beneﬁt, and acceptability
curves. Other issues to consider with sample size calculation
include using averages when presenting cost data, making the SD
explicit; being realistic about the number of dengue cases that
can be used for the study; and whether sampling occurs through-
out the year or only during the peak of a dengue season. Annex 1
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
vhri.2015.06.001 describes the steps for sampling calculations.
Step 6: Deﬁning the Unit of Analysis
The next step is to deﬁne the unit of analysis that relates to the
resources used for the treatment of a dengue case or outbreak
and its associated costs. The unit of analysis is determined by the
decision problem. For example, the unit of analysis for health
care costs is a dengue case recruited in a health care facility. For
each hospitalized case, a clinical pathway or management
practice (e.g., health care service activities) based on daily clinical
practice in the hospital should be identiﬁed. This includes
information about days in the hospital, consultation, tests, and
drug treatments. If, however, the decision problem relates to
dengue outbreak control and surveillance spending, the unit of
analysis would then be dengue outbreak. Different cost
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education, and communication before, during, and after an out-
break) would need to be considered. The sources collecting cost
data during an outbreak will be primarily government-based, but
there will be other sources including household surveys and
surveys to outbreak response personnel that should be
considered.
Regional experts advocate the use of the framework devel-
oped by Bärnighausen et al. [28,29] when deﬁning the unit of
analysis because dengue affects the economy and health systems
of endemic countries in various ways and across various sectors
of the population. Although this framework was developed to
assess the broader economic beneﬁts of vaccination (as opposed
to estimating costs), we need to think about a broader perspective
when costing dengue to ensure the full range of costs associated
with dengue is accounted for. When adopting this broader
perspective, we will capture the true costs that accrue over the
lifetime of an individual with dengue. These include the costs
incurred during the acute phase of the illness and costs that
accrue over time when multiple episodes of dengue occurred or
during dengue outbreaks. The recommendation from the experts
is thus to include the health care costs (e.g., hospitalized and
outpatient costs), program costs (e.g., vector control, education
and community mobilization, and surveillance), productivity
costs (costs associated with missed work and reduced capacity
and/or productivity at work), and multisectoral costs (e.g., income
from tourism, foreign direct investment ﬂows, long-term fatigue
and depression costs, outbreak control, and surveillance spend-
ing) to inform decision making regarding dengue control and
prevention interventions.
Step 7: Identifying Cost Items
Once the unit of analysis is deﬁned, the next step is to identify all
the activities that relate to dengue control and prevention.
Table 2 provides a “menu” of cost components for dengue cost
evaluations and these include 1) health care activities, 2) program
activities, 3) activities related to productivity, and 4) intersectoral
activities. Each activity comprises different cost items such asTable 2 – A proposed “menu” for cost components.
Health care costs  The unit of analysis for this component is a d
 To have representativeness of the local health
○ All subsystems (public, private, and other s
○ Different levels of complexity of services (p
 The cost per case estimated is multiplied by th
epidemiological studies) to obtain the econom
 Medical direct (number and type stratiﬁed by l
nurse visits, tests/examinations, drugs, monito
 Medical nondirect (number and type): food, lod
 Indirect: absenteeism (work/school) for patient
Program costs  The assessment of these costs should include
○ Vector control;
○ Education and community mobilization;
○ Surveillance.
 These costs should be obtained in a period of
annual costs for each component.
Productivity loss  This relates to long-term costs and includes
○ Caretaker wages lost or school absence res
○ Productivity losses that occur because of p
○ Productivity losses that occur because of d
Multisectoral costs  Income from tourism;
 Foreign direct investment ﬂows;
 Long-term fatigue and depression costs;
 Outbreak control and surveillance spending.staff, equipment, and consumables. The number of cost items
contained within an activity will vary depending on the level of
detail desired or available.
For health care costs, the unit of analysis for this component
is a dengue case recruited in a health care facility (hospital,
outpatient). To have representativeness of the local health
system, data on costs should be collected in all subsystems
(public, private, and other sectors) and in different levels of
health services (primary, secondary, and tertiary). For program
costs, the assessment of the dengue program global costs should
include the following three components: vector control, educa-
tion and community mobilization, and surveillance. These costs
should be obtained during high- and low-transmission seasons.
Costs associated with loss of productivity are long-term and
include caretaker wages lost or school absence resulting from
dengue-related illness, productivity losses that occur because of
premature death, and productivity losses that occur because of
disability as a result of dengue. Costs associated with intersec-
toral activities include income from tourism, foreign direct
investment ﬂows, long-term fatigue and depression costs, out-
break control, and surveillance spending.
Estimating costs decisions need to be made regarding the
level of precision required. The spectrum of precision ranges
from a bottom-up costing approach, in which individual compo-
nents of resource use are identiﬁed and measured, to a top-down
costing approach, in which larger intermediate products such as
a hospital day are used. The choice between bottom-up and top-
down costing depends on how sensitive the results of the costing
study are likely to be to the individual cost estimates and on the
degree of precision required in the analysis and the time and
resources required to produce a detailed breakdown of unit costs.
Beneﬁts of a bottom-up costing approach include the precision
and detail of the data, as well as the transparency of results,
allowing analysts in other settings to determine how relevant the
resource use patterns are to their situation. Conversely, top-down
costing allocates a total budget to speciﬁc services (e.g., staff
salary for vaccination). The choice ultimately depends on how
accurate cost estimates need to be given the study perspective.
The least precise estimates are likely to be based on top-downengue case recruited in a health care facility.
system, data on costs should be collected in
ectors);
rimary, secondary, and tertiary).
e number of cases (coming from the surveillance system or
ic burden of health care consumption.
evel of assistance including public and private sector): medical visits,
ring/observation, hospital cost.
ging, transportation, treatment by patient (out-of-pocket).
and caregiver.
the following three components:
time including a high- and low- transmission season to estimate the
ulting from dengue-related illness;
remature death;
isability as a result of dengue.
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bottom-up costing. Annex 2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.vhri.2015.06.001 describes the data
requirements for costing fever cases and outbreaks.
Methods of controlling for costs include the use of modeling
through decision analysis, the exclusion of resource use attrib-
utable to the study, and modifying the study in selected centers.
Each of these methods has its own advantages and disadvan-
tages; however, none obviates the need for information on
resource utilization outside the study setting. Where existing
data are scarce, various techniques can be used to obtain such
information, including the use of medical records, expert panels,
observational studies, and prospective data collection. The use
of medical records to collect data retrospectively may prove
problematic in low- and middle-income countries; hence, the
use of either expert consultation or prospective data collection is
likely to provide information that is more accurate. Expert
opinion can be obtained using physician interviews, Delphi
panels, nominal group processes, or expert roundtables; however,
there are currently no formal guidelines on their use. Similarly,
there is little consensus on the numbers and types of facilities
that need to be included if data are collected prospectively.
Data on costs can be obtained from various sources including
clinical trials, observational studies, meta-analysis, case reports,
databases, expert panels, and administrative records. In practice,
the evidence required to evaluate the costs of medical interven-
tions and related resources is rarely present in a single source.
The expert panel recommends that cost data be taken from a
number of different sources, and synthesized using analytical
structures called models.
Steps 8: Measuring and Valuing Cost Items
To calculate the total costs of disease or an intervention,
quantities of resources used are multiplied by an assigned value.
This value is called a unit cost. The costs associated with dengue
to the health care system can be estimated by combining the
number of each type of event (e.g., hospitalized dengue and
ambulatory dengue) with information on the costs associated
with the event. For hospital and ambulatory events, these can be
partitioned into the cost of the visit (including facilities and
personnel) and the cost of the resources used for treatment
(speciﬁc tests and medications). The valuation of resource use
in monetary units must be consistent with the perspective of the
analysis. If the perspective of a health care provider is consid-
ered, only those costs for which the health care provider is
accountable for should be included. If a societal perspective is
taken, all costs are taken into account regardless of whose budget
is affected or where in society they occur.
Experts recommend using a mixed costing methodology to
address the issue of data availability constraints that are com-
mon in dengue-endemic countries of the region. A mixed costing
methodology would entail minimizing data collection in areas
where a small share of total costs exists and maximizing the
ability to measure the difference in costs between patients in
areas where there is a large share of total costs. For example,
when estimating the cost of a dengue outbreak, the bottom-up
costing approach should be applied to estimate the costs asso-
ciated with surveillance and vector-control programs and indirect
costs that include loss of working hours because these are known
to be key cost components of a dengue outbreak. In contrast, a
top-down costing approach should be used when estimating the
direct costs that include laboratory, technical services, drugs,
consumables, fees, and other resources because these are drivers
of the cost of an outbreak.
Several issues regarding the valuation of resource use data
exist, including the use of average versus marginal costs,opportunity costs versus hospital charges, center-speciﬁc versus
average costs, as well as methods of valuing productivity
changes. For example, marginal cost refers to the change in total
costs when producing an additional unit of input, and the
marginal cost of an activity depends on the time frame of the
analysis. As an approximation, it is quite common to estimate
marginal cost using average costs. This is done because average
cost is generally easier to measure. In the long run, average costs
will be a good approximation to marginal costs because all
inputs, including labor/capital, become variable, but average
costs are generally not good approximation in the short run
where costs are ﬁxed and only a few may be variable. Staff time
(and associated costs) may be ﬁxed in the short run, whereas
drug costs will generally be variable.
For each country, baseline cost estimates can be generated
using resource use information from multicenter hospital-based
or community-based observational study and facility-speciﬁc
cost data. Two additional simpler approaches can also be used:
physician interviews and extracting estimates from the WHO-
CHOICE project (Universidad Nacional Autónoma de México,
personal communication, 2012). The ﬁrst approach offers the
advantage of using empirical methods to reﬂect costs (direct
medical, nonmedical, and indirect costs). The step-down costing
method can be used here to measure unit (average) costs. This
method was preferred in the present analysis because of the
careful description of hospital and ambulatory costs. The
responses of local physicians can also be used to augment the
estimation of resource utilization and unit cost data. The third
and last approach uses generalized unit cost data derived from
local and national sources and secondary data to estimate direct
medical costs of dengue.
The steps for measuring outbreak costs include 1) conﬁrma-
tion of an outbreak; 2) estimation of the number of people
infected during an outbreak; 3) calculation of the outbreak cases
times the cost per outbreak case; 4) gathering of information on
budget impact (e.g., vector-control strategies, surveillance, media
campaigns, tourism impact, and medical personnel) from govern-
ment ofﬁcials at all relevant levels; and 5) investigation of
complete budget expenses by individuals or their families in
response to an outbreak (e.g., vector-control program and tour-
ism impact). Additional recommendations regarding the steps for
measuring outbreak costs include the following: 1) be systematic
about the scope, scale, perspective, and measurement approach
used; 2) understand the health care system where the outbreak
occurs; 3) account for differences in the design and conduct of
these studies; 4) focus data collection for future costing on
disease that is considered to be the most costly but also the
most frequent; and 5) understand that small changes in costs can
produce large ﬂuctuations in economic burden and target efforts
on getting those costs accurately assessed.
Information on where patients are treated for dengue can be
collected from a number of sources. Demographic and health
surveys, which are undertaken periodically in a number of
countries, normally include a section on the treatment of infec-
tious diseases such as dengue. Data are usually available on the
percentage of cases taken to a health facility or provider. Other
likely sources for this information include health interviews with
doctors, nurses, and/or Ministry of Health ofﬁcials and published
articles from neighboring or comparable countries. A detailed list
of these sources is provided in Annex 3 in Supplemental Materi-
als found at http://dx.doi.org/10.1016/j.vhri.2015.06.001.
A study being conducted in many sites and in many countries
presents difﬁculties in aggregating and analyzing cost data. The
analyst is faced with a choice of whether the cost data should be
country-speciﬁc or pooled across countries. A further consider-
ation is important here: namely, whether to combine local unit
costs with local resource use data or combine local unit costs
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including the entire study cohort. Estimates of average resource
use (and the cost of such resource use) based on information
from a single country are subject to uncertainty, with wide
conﬁdence intervals. Using resource use data from the entire
study may suffer from the potential lack of representativeness of
these data for an individual country of interest. Access and use of
health services, treatment patterns, and costs vary greatly among
countries. These are considered to be data of low transferability.
A description of a dengue costing evaluation can be found in
Annex 4 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.vhri.2015.06.001.
Two methods are generally used to make cross-country
comparisons of health care costs. These comprise purchasing
power parity (PPP) conversion factors and ofﬁcial exchange rates.
These methods have been used widely to convert values of
different countries into a common denominator. The agreed
deﬁnition of ofﬁcial exchange rates is that they are prices (rates)
at which currencies are bought and sold on the international
market. International comparisons based on market exchange
rates can greatly overestimate or underestimate the value of the
economic activity of a country. Because many goods and services
are not traded in international commerce, market-based
exchange rates may not reﬂect the relative values of goods.
They may reﬂect only the equalization of prices for internation-
ally traded goods and not the prices of nontraded goods such as
health care. Hence, a given sum of money converted into differ-
ent currencies using ofﬁcial exchange rates may not necessarily
buy the same quantity of goods and services in all countries. In
this way, exchange rates fail to address the issue of compara-
bility arising from differences in price levels between countries,
and their applicability in economic studies may be limited and
only for the purpose of comparing it with other alternative
methods.
In contrast, PPP conversion factors are virtual exchange rates;
they are the numbers that are used to compare the standard of
living of two countries. PPP-adjusted gross domestic product or
gross national income values are the values converted from local
currency unit into US dollars because the United States is used as
the base country. They estimate the units of a country’s currency
that would be required to purchase the same baskets of goods
that a dollar would buy in the US market, thus eliminating the
differences in price levels between countries. The average coun-
try is based on a composite of all participating countries, so no
single country acts as the base country. Although they are an
improvement on exchange rate conversions, a number of meas-
urement problems have been recognized with the use of PPP
conversion factors. This is partly because PPP conversions make
comparisons of aggregate expenditure across countries, rather
than of the prices of health care interventions. PPP conversion
factors do not account for health care–speciﬁc weights, which are
likely to be different from the relative weights within the basket
of goods used to construct PPP conversions.
An even bigger problem is related to the value that individuals
in different countries attach to different components of health
care or to differences in the composition of that basket. Moreover,
PPP conversion factors are estimated every 5 years only and
health-speciﬁc PPPs are measured on a very small sample of
items. In addition, there is a bias toward pharmaceutical prices
with health-speciﬁc PPPs. Two hundred and twenty-eight prices
out of 294 prices for health PPPs are based on pharmaceutical
prices. This makes the quality of the data at more detailed level
(such as health) poor, particularly for developing countries. Given
all these caveats, the expert panel recommends that all monetary
ﬁgures should be reported in their local currency and interna-
tional dollars for consistency purposes and to enable cross-
country comparisons.Step 9: Handling Uncertainty
There are two main areas of uncertainty in a costing study:
parameter uncertainty and modeling uncertainty. Sources of
data, extrapolation, and analytic methods contribute substan-
tially to parameter uncertainty. Inadequate sample sizes, skewed
cost data, discount rates, and unit costs may introduce additional
parameter uncertainty.
Parameter uncertainty refers to the numerical values of the
parameters that are unknown and entail uncertainties in the
estimates of disease epidemiology, treatment interventions, and
costs associated with treatment. These parameters may be
uncertain because of sampling variation, disagreement about
the appropriateness of the range of plausible values that are
used, lack of information regarding disease epidemiology, and
disease costs. The implications of these uncertainties are partic-
ularly important in the assessment of potential health care policy
options, for example, with respect to the selection of control and
prevention strategies for dengue. A few countries have developed
methodologies to deal with this type of uncertainty. Mexico, for
example, developed a Program, Actions, Activities, Tasks and
Inputs methodology to deal with model uncertainty by compar-
ing the costs derived from standard methodology with real cost
estimates (Universidad Nacional Autónoma de México, personal
communication, 2012).
Modeling uncertainty relates to the structure and process of
the model. Model structure uncertainty exists when there is
ambiguity about the correct method for combining model param-
eters. In contrast, model process uncertainty is introduced by the
combination of decisions made by the analyst. Limited studies
discuss the importance of addressing modeling uncertainty in
costing models to make better inferences about the true level of
uncertainty.
Although the use of modeling is often unavoidable, there are
certain concerns about costing models that require attention. First,
bias can be introduced when data from sources with inadequate
sample sizes, poor methodology, and confounding variables are
incorporated into a model. Second, models rely on a number of
assumptions regarding the underlying disease process, relation-
ships between risk factors and clinical outcomes, and extrapola-
tion of data into ﬁnal end points. Third, models are often criticized
for their lack of transparency regarding the inputs, outputs, and
key assumptions that have been incorporated.
Selection bias can be introduced in the design of the costing
model. In this instance, factors that are likely to be the chief
dependents of outcomes and the size or degree of such depend-
ent on outcomes may be unknown. Models rely on a number of
assumptions regarding the underlying disease process, relation-
ships between risk factors and clinical outcomes, and extrapola-
tion of data into ﬁnal end points. In the trial setting, for example,
treatment is randomly assigned across the patient population.
Within the context of modeling design, however, it is determined
by other inﬂuencing factors, such as patient attributes, disease
characteristics, or sometimes the preference of the prescribing
physician. Selection bias occurs when treatment choice is no
longer the only differentiating factor between patients.
Selection bias can also be introduced when data from sources
with inadequate sample sizes, poor methodology, and confound-
ing variables are incorporated into a model. Selection bias
affecting who received or did not receive an intervention may
limit the value and generalizability of cost data collected. Infor-
mation about the costs of medical and nonmedical interventions
is not always collected on a trial-based study and secondary data
sources, such as a claims database, may be used to ﬁll additional
information needed for the study. Other resource use items that
can be overlooked include out-of-pocket expenses, time waiting
for treatment, informal caregiver time, and loss in productivity.
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hurdles to overcome when interpreting the results of cost
studies, and it is compounded by the fact that any one of several
factors, including age, sex, indication, and severity, can interact
to confuse or distort the outcome of treatment (confounding
bias). One simple way to account for confounding bias is to
include the likely “confounding” factors (e.g., age, sex, etc.) in a
regression model in which the treatment costs can be corrected
for the other variables. Although this is a relatively simple and
straightforward process, cost calculations can become quite
complex if adjustments must be made for many variables. An
alternative to this approach is to match patients according to one
or more variables, or, in cases in which there are many possible
covariates, applying propensity scores can be helpful.
Sensitivity analysis and other statistical techniques are per-
formed to test the impact on results of changes in uncertain or
unﬁxed parameters and models and assess the robustness of the
cost estimates to changes in assumptions and the values of the
input variables. Sensitivity analysis involves three steps: 1)
identifying the uncertain parameters for which sensitivity anal-
ysis is required; 2) specifying the plausible range over which
uncertain factors are thought to vary; and 3) calculating study
results based on combinations of parameters varied. In addition
to providing an overall assessment of conﬁdence in the cost
estimates, sensitivity analysis provides a method for identifying
variables that are likely to affect signiﬁcantly ﬁnal estimates of
the economic burden of disease.Discussion
As with many economic concepts, cost is not uniquely deﬁned.
This is of particular importance in estimating the costs of disease
because such studies are context-speciﬁc. Dengue costing studies
must be designed to reﬂect the scope of the study, study
perspective, time horizon, and target population, among other
methodological issues.
A true estimate of the overall cost of dengue can be used for
three major purposes and types of analysis: Raising awareness of the economic burden of dengue: By
demonstrating the economic impact of dengue, politicians,
leaders, and policymakers can become convinced of the
problem and be encouraged to engage in dengue prevention
and control strategies. Planning and budgeting for dengue prevention and control:
An estimate of the resources used to treat dengue can be used
in an analysis of health sector expenditures and priorities. Cost-effectiveness analysis of interventions for prevention
and control of dengue: Treatment costs and indirect costs of
dengue can be saved if effective interventions are introduced
to prevent and reduce the severity of dengue. The cost
estimate is thus an integral part of a cost-effectiveness
analysis of potential interventions, such as○ Promotion of vector-control strategies;
○ Dengue immunization;
○ Improving environmental conditions in urban and rural
areas; and○ Promoting personal and domestic hygiene.In this article, we presented a step-by-step guide for estimating
the cost of dengue in endemic countries of the region. The guide-
line for costing dengue is the result of a collaborative effort,
drawing on the direct input of local experts attending the work-
shop. The combined experience of the local experts from a range of
countries in the Americas (Brazil, Colombia, Jamaica, El Salvador,
Mexico, Panama), all of which have practical experience in theestimation of disease costs, was applied. Experts agreed that the
identiﬁcation, measurement, and valuation of costs associated with
dengue fever should be consistent with the perspective in question.
Cost studies will vary depending on the context in which the
study is conducted and the decision problem addressed. Health
care costs, non–health care costs, and broader economic costs
should be considered in the costing study. Validated sources should
be used for the unit costs, and standardized proxies for unit cost
can be used when needed. Measurement of resource use should be
done by means of observations (e.g., surveillances studies) or
derived from national surveillance databases or the literature.
Key points raised by experts when costing dengue cases and
outbreaks include the ability to be systematic about the scope,
scale, perspective, and measurement approach used, to account
for differences in the design and conduct of these studies, to
focus data collection on future costing on disease that is consid-
ered to be the most costly but also the most frequent, and to
understand that small changes in costs can produce large
ﬂuctuations in economic burden and target efforts on getting
those costs accurately assessed.
The guidelines discussed previously are intended to be regional
in scope. They aim to provide an overview of the state of the ﬁeld
of costing dengue and a discussion of the methods used in cost
study in a manner that should be accessible to persons with some
familiarity with a COI study. Because such a study has many
different methodological components built from extensive theo-
retical and operational evidence of their comprising disciplines, a
number of issues cannot be dealt with in depth. For this reason,
areas of priority to workshop participants were highlighted.
Although there is no single theoretically correct approach to
developing guidelines for costing dengue, experts generally
adhered to certain principles including the adoption of a societal
perspective; the inclusion of all relevant costs and effects; the use
of an adequate sample size; and the optimal collection and
valuation of unit cost data for use in multicountry settings. Beyond
these core principles, several concerns remain regarding the use of
sensitivity analysis in uncertainty areas, data representativeness,
and cost variance within and across countries.Conclusions
Costing evaluations provide a critical input into economic eval-
uations. The recommendations presented in this article can be
used to estimate the cost of dengue cases and outbreaks in
endemic countries of the region. Through this guideline the
expectation is to facilitate the development of dengue cost
studies in various countries of the region, leading to the provision
of better information for the determination of regional public
health policies to counter dengue. Over time, the underlying
estimation methodologies will improve and expand to include
other economic evidence of dengue. We believe that the current
guideline will help to improve the quality of dengue costing
studies and permit comparison of dengue cost estimates across
the countries of the region.
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